CTMX
CytomX Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
CytomX Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Fund move
Fund move
No thesis.
CytomX Therapeutics, Inc.
2.37
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | FMRFMR | $122.7M | 15.22% | +2.38% | |
| 2 | Kynam Capital ManagementKynam | $81.4M | 10.10% | +44.56% | |
| 3 | BlackRockBlackRockindex-like | $65.8M | 8.17% | +235.86% | |
| 4 | Bank of AmericaBank of America | $56.6M | 7.02% | +47.83% | |
| 5 | State StreetState Streetindex-like | $44.1M | 5.47% | +107.42% | |
| 6 | Perceptive AdvisorsPerceptive | $39.1M | 4.86% | +3.37% | |
| 7 | Vanguard Capital ManagementVanguardindex-like | $32.0M | 3.97% | −2.38% | |
| 8 | Point72 Asset ManagementPoint72 | $29.3M | 3.63% | −0.82% | |
| 9 | Wellington Management GroupWellington | $19.4M | 2.41% | +44.26% | |
| 10 | VR AdviserVR Adviser | $18.7M | 2.32% | −50.09% | |
| 11 | Baker Bros. AdvisorsBaker Bros. | $18.7M | 2.32% | 0.00% | |
| 12 | Geode Capital ManagementGeodeindex-like | $17.5M | 2.18% | +126.40% | |
| 13 | Elmind CapitalElmind Capital | $17.1M | 2.12% | 0.00% | |
| 14 | Nextech InvestNextech Invest | $16.7M | 2.07% | 0.00% | |
| 15 | Two Sigma InvestmentsTwo Sigma | $15.5M | 1.92% | +52.49% | |
| 16 | Eversept PartnersEversept Partners | $13.3M | 1.66% | +11.60% | |
| 17 | UBS GroupUBS | $13.0M | 1.61% | +11.16% | |
| 18 | SirenSiren | $13.0M | 1.61% | 0.00% | |
| 19 | ADAR1 Capital ManagementADAR1 | $12.6M | 1.57% | −1.32% | |
| 20 | Citadel AdvisorsCitadel | $12.5M | 1.55% | −43.55% | |
| 21 | Marshall WaceMarshall Wace | $11.3M | 1.41% | −26.92% | |
| 22 | Woodline PartnersWoodline Partners | $7.7M | 0.95% | +1.97% | |
| 23 | Goldman Sachs GroupGoldman Sachs | $7.5M | 0.93% | +37.25% | |
| 24 | Dimensional Fund AdvisorsDimensional | $7.0M | 0.87% | −3.66% | |
| 25 | Qube Research & TechnologiesQube Research & Technologies | $6.8M | 0.85% | −18.89% |
179 managers report $805.8M of CytomX Therapeutics on form 13F for the quarter ended Jun 30 '26. 19 of them hold 80% of it; FMR is largest at 15.22%.
Linked news
Expected move
Inputsstraddle ±34.5%
spot 2.34exp Nov 20ATM strike 2ATM straddle 0.95IV 216%